The standard protocol begins with a low dose (0.25 mg semaglutide or 2.5 mg tirzepatide weekly) and increases every 4 weeks to minimize gastrointestinal upset
This is accelerating adoption across hospitals, specialty obesity clinics, and endocrinology practices, thereby driving market growth
Treatment of children and adolescents with 1.3ug/kg/day thyroxine for 24 months was shown in a recent study to cause significant reduction in thyroid size in patients with Autoimmune thyroiditis, but not affect antibody levels, or significantly alter TSH or freeT 4
According to the criteria (false discovery rate 0.05 and unique peptide number 2), 1469 proteins were identified from groups T1T4
If anything, this study simply affirms what we have been seeing directly in patient care that is, people rapidly regain weight once they stop obesity medications, says Kushner